A breath of fresh air for COPD management
We’re here to support you on your mission to do your best for your patients and your NHS.
Optimising COPD medicines can help you balance your clinical, cost and carbon priorities. Create an account and follow our step-by-step guide to identify, develop and deliver a bespoke COPD therapy optimisation project for your area.
Our planning tools, customisable calculators and personalised prescribing trends allow you to predict the speed and impact of your project. So when it comes to COPD therapy options, both you and your patients can breathe easy.
Discover an optimised future. Discover Value.GSK
Your 3 steps to an optimised future for your health economy
Why optimise?
Discover the impact COPD therapy optimisation could have on your patient outcomes, cost savings and carbon footprint.
Where to optimise?
Use our personalised prescribing trends to identify new opportunities to optimise in your area.
How to optimise?
Target, plan and resource your optimisation journey using our project planning tools.
Our respiratory products
GSK respiratory products on this site include:
Trelegy Ellipta
(fluticasone furoate/umeclidinium/vilanterol)
Anoro ▼ Ellipta
(umeclidinium/vilanterol)
Relvar Ellipta
(fluticasone furoate/vilanterol)
Incruse ▼ Ellipta
(umeclidinium)
Seretide Accuhaler
(salmeterol xinafoate/fluticasone propionate)
Explore COPD medicine trends in
On average, 46% of medicine prescribing in England are on single inhaler triple therapy (SITT) medication.
Higher LAMA therapy prescribing we use as a proxy for higher multiple inhaler triple therapy prescribing.
On average, 31% of medicine prescribing in England are on dry powder inhalers (DPI) devices.
Classes included in device graph: LAMA, ICS/LABA/LAMA, LAMA/LABA, ICS/LABA
Calculations and assumptions
Class and Device Data: From GP Practice Prescribing data 2
National average: Calculated for England, Scotland or Wales depending on health economy selection
NB. Certain LAMA products can also be used for Asthma, opportunity is estimated only.
Find the average in your area and see how you compare to leading areas and the national average when you register for a free account today.
How do you compare to other health economies and the national average?
Benchmark your COPD class prescribing against health economies in your region and discover how you perform over time.
Change your location
This chart shows how the percentage breakdown of LAMA, LAMA/LABA and ICS/LABA/LAMA therapies in your area compares to your peers to help benchmark therapy prescribing.
NICE COPD treatment guideline recommendations below are for classes of medicines, not specific products - NICE COPD treatment guidelines now include1:
- NICE guidelines recommend the LAMA/LABA class as first-line maintenance therapy in specific COPD patients1
-
- NICE recommends the LAMA/LABA class as first-line maintenance therapy in patients with no asthmatic features/features suggesting steroid responsiveness who remain breathless/have exacerbations despite short-acting bronchodilator therapy.
- Patients should have spirometrically confirmed COPD and also have been offered/received treatment for tobacco dependence (if smokers), had optimised non-pharmacological management and received relevant vaccinations.
- LAMA/LABAs are indicated as maintenance bronchodilator treatments to relieve symptoms in adult patients with COPD.
- Single inhaler triple therapy (SITT) as an option where ICS+LABA+LAMA is required. NICE also recommends minimising the number of inhalers and the number of different types of inhaler used by each person as far as possible1
This chart shows how the percentage breakdown of MDI, DPI and FMI inhalers in your area compares to your peers to help benchmark device prescribing.
Classes included in device graph: LAMA, ICS/LABA/LAMA, LAMA/LABA, ICS/LABA
Calculations and assumptions
Class and Device Data: From GP Practice Prescribing data 2
National average: Calculated for England, Scotland or Wales depending on health economy selection
Peer health economy selection: Selection of peers based on those peer health economies with lowest percentage of LAMA vs LABA/LAMA & ICS/LABA/LAMA
NB. Certain LAMA products can also be used for Asthma, opportunity is estimated only.
Calculations and assumptions
Class and Device Data: From GP Practice Prescribing data2
National average: Calculated for England, Scotland or Wales depending on health economy selection
Peer health economy selection: Selection of peers based on those peer health economies with lowest percentage of MDI vs DPI & FMI
NB. Certain LAMA products can also be used for Asthma, opportunity is estimated only
Register now to explore your optimisation opportunities and use our calculators and project planner to deliver a bespoke COPD therapy optimisation project for your area.
Discover the benefits of optimising in [LOCATION]
Clinical
The British Lung Foundation found that 37.1% of patients with COPD had not received their annual review in 20213
The coronavirus pandemic has caused a backlog of patients in the NHS
Cost
COPD is estimated to cost the NHS £1.9 billion a year and is the second largest cause of emergency hospital admissions4,5
COPD is estimated to cost the NHS each year
Carbon
NHS target for carbon reduction requires a 50% reduction in the carbon impact of Inhalers by 20306
NHS required carbon reduction in Inhalers by 2030
Discover the benefits of optimising in [LOCATION]
Discover the clinical benefits of Trelegy and Anoro Ellipta and calculate the cost and carbon impacts that optimising therapies could have on your region – and how it might improve your patients’ lives.
Trademarks are the property of their respective owners.
Anoro Ellipta was developed in collaboration with INNOVIVA.
Data processing and update
Practice prescribing data processing:
- Processing: GP practice prescribing data2 presented in this model has undergone a process of standardisation to ensure that as accurate as possible comparisons can be drawn. For example, raw GP practice prescribing data presents some inhaler quantities as '1' which is equivalent to 1 month of treatment typically, but others (e.g. in the instance of inhalers which take capsules) as '30'. Every effort is made to present the data as it is published by the publisher. Due to the workload involved in performing this standardisation, not all classes of medicine within the respiratory market have been standardised and therefore not all are shown
- Update: data is updated on a monthly basis
Management of data across NHS geographies:
- A geographical hierarchy is built and maintained by GSK based on data published by the NHS. This hierarchy matches prescribers to health economies and allows the model to amalgamate practice level data up to health economy level (either an individual health economy or any combination of health economies)
- Please note we make all reasonable effort to ensure data are as per the latest published information by the respective NHS organisations. Therefore where, for example, a new practice has been opened, unless this has been updated by the NHS data will not be included for this practice
For illustrative purposes only
GSK makes no representation or warranty as to the suitability of the output of the model for any particular purpose.
References and glossary
- National Institute for Health and Care Excellence (NICE). 2019. Chronic obstructive pulmonary disease in over 16s: diagnosis and management [NG115]. Available at: https://www.nice.org.uk/guidance/ng115 (Accessed March 2022)
- GPrX (Updated monthly from GPrX) Practice prescribing data - This data is provided by GPrX Data Ltd from published UK NHS data sources. The NHS data are protected by copyright and re-used under the terms of an Open Government License for public sector information which can be viewed at: http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3 with the permission of NHS Business Services Authority (NHS BSA), HSC Northern Ireland Business Services Organisation (HSCNI BSO), NHS Wales Shared Services Partnership (Primary Care Services) (NWSSP PCS) and NHS National Services Scotland Information Services Division (NSS ISD). Copyright © 2022. All rights reserved.
- British Lung Foundation. (2021) Failing on the fundamentals: Insights from those living with chronic obstructive pulmonary disease (COPD) around the UK. Pages 3-4. Available here: https://cdn.shopify.com/s/files/1/0221/4446/files/COPD_survey.pdf?v=1636977618&_ga=2.105242379.925192035.1647002232-1336644656.1646311648 (Accessed March 2022)
- Trueman, D., Woodcock, F. and Hancock, E. 2016. Estimating the economic burden of respiratory illness in the UK. British Lung Foundation. Pp 4-5 Available here: http://allcatsrgrey.org.uk/wp/download/respiratory_diseases/PC-1601_-_Economic_burden_report_FINAL_8cdaba2a-589a-4a49-bd14-f45d66167795.pdf (March 2022)
- National Institute for Health and Care Excellence (NICE). 2015. Quality standards and indicators briefing paper: Chronic obstructive pulmonary disease (COPD) update. NICE pp4 Available here: https://www.nice.org.uk/guidance/qs10/documents/briefing-paper (March 2022)
- British Thoracic Society (2020) Position Statement the Environment and Lung Health. Available at: Environment and Lung Health Position Statement 2020 (17).pdf (Accessed March 2022)
October 2022 PM-GB-RS-WCNT-200010 (v4)